key: cord-0930244-wauikjy8
authors: Ihlow, Jana; Michaelis, Edward; Greuel, Selina; Heynol, Verena; Lehmann, Annika; Radbruch, Helena; Meinhardt, Jenny; Miller, Florian; Herbst, Hermann; Corman, Victor Max; Westermann, Jörg; Bullinger, Lars; Horst, David; von Brünneck, Ann-Christin; Elezkurtaj, Sefer
title: B Cell Depletion and Signs of Sepsis Acquired Immunodeficiency in Bone Marrow and Spleen of COVID-19 Deceased
date: 2021-01-02
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.12.078
sha: 2d41cc5323e2361ed97ea747050c83835eb0821e
doc_id: 930244
cord_uid: wauikjy8

OBJECTIVES: In COVID-19, the adaptive immune response is of considerable importance and detailed cellular immune reactions in the hematological system of patients with severe SARS-CoV2-infection are yet to be clarified. METHODS: Here, we provide a morphologic characterization of both bone marrow (BM) and spleen (SPL) in 11 COVID-19 deceased with respect to findings in the peripheral blood and pulmonary SARS-CoV-2 burden. RESULTS: In the BM, we found activation and left shift in at least 55% of patients, which was mirrored by anemia and granulocytic immaturity in the peripheral blood as well as thromboembolic events. In the setting of abscess-forming superinfection of COVID-19 pneumonia, we found signs of sepsis acquired immunodeficiency. Furthermore, we observed a severe B cell loss in the BM and/or SPL in 64 % of COVID-19 patients, which was reflected by lymphocytopenia in the blood. These findings were associated with higher pulmonary SARS-CoV-2 load and only marginally decreased T cells as compared to patients with B cell preservation. CONCLUSIONS: Our results suggest that sepsis-related immunodeficiency might aggravate the progress of COVID-19. Furthermore, our findings indicate that lymphocytopenia in COVID-19 is accompanied by B cell depletion in hematopoietic tissue, that might impede the humoral immune response to SARS-CoV-2.

Over the past months, the pandemic spread of SARS-CoV-2 (severe acute respiratory syndrome virus 2) has claimed more than 1.5 million lives (WHO, 2020) . Current mortality rates with severe COVID-19 (coronavirus disease 2019) are approximately 5%, which is relatively high as compared to death from influenza (Faust and del Rio, 2020 , Iuliano et al., 2018 , WHO, 2020 .

Although pulmonary factors such as diffuse alveolar damage and pneumonia are major immediate causes of death in patients with COVID-19, recent studies have proposed that endotheliitis and thromboses contribute to the severity of pulmonary damage (Ackermann et al., 2020 , Bryce et al., 2020 , Lax et al., 2020 , Levi et al., 2020 , Varga et al., 2020 . Nevertheless, deduction of therapeutic algorithms from this knowledge is difficult. This reflects the heterogeneity of the clinical outcome with SARS-CoV-2 infection.

With regard to the pathophysiology of COVID-19, T cell mediated immunity seems to play a major role, which has been linked to severe lymphocytopenia in the blood (Terpos et al., Zheng et al., 2020) . Recent findings also indicate a T-cell mediated germinal center atrophy in the lymph node and the spleen with loss of germinal center B cells in early COVID-19 (Kaneko et al., 2020) . Here, we provide a post-mortem analysis of bone marrow (BM) and splenic tissue (SPL) in patients that died of COVID-19, which substantially contributes to recent findings in the pathogenesis and adds further explanation to the lack of durable immune responses with SARS-CoV-2 infection.

Post-mortem examination was performed in a total of 15 patients. 11 of these patients had PCRconfirmed SARS-CoV-2 infection and were diagnosed with COVID-19. The remaining 4 patients died from cardiac conditions and were matched for age, thereby serving as a control group. On the legal basis of §1 SRegG BE of the autopsy act of Berlin and §25 of the German Infection Protection Act, autopsies were either performed at Charité University Medical Center Berlin or at Vivantes Hospitals Berlin. The study was performed in accordance with local ethical guidelines (ethics committee approval: EA2/066/20) and the declaration of Helsinki. Written consent was obtained from all next of kin. Clinical data were obtained from clinical records or death certificates.

We performed complete autopsy in 11 patients with COVID-19 and 4 control patients. Proper safety precautions were undertaken and autopsies were performed in an enclosed space according to the safety guidelines (CDC, 2020) . For histopathology, we obtained pulmonary samples, BM from vertebral bodies and splenic tissue.

BM and SPL were fixed in formalin and BM then was decalcified with a solution of 20% Ethylenediaminetetraacetic acid (EDTA) for 8 hours overnight. Samples then were dehydrated and (1:100, Dako), CD4 (1:20, Leica), CD8 (1:100, Dako), CD138 (1:25, Dako), human leucocyte antigen Isotype DR (HLA-DR, 1:25, Leica), programmed cell death protein and ligand 1 (PD-1, 1:100, Epitomics and PD-L1, 1:200, Cell signaling), or Caspase 3 (1:400, Zytomed). A horseradish peroxidase (HRP)-conjugated secondary antibody (Leica) then was applied for 32 minutes. In the same manner, SPL-slides were stained with primary antibodies against Ki67 (1:100, Dako), CD20, CD3, CD4, CD8, CD3, CD34, CD61, CD68, HLA-DR, and PD-L1. This was followed by a chromogen 3,3′-diaminobenzidine-tetrahydrochloride (DAB) application for 8 minutes and a counterstaining with hematoxylin (Ventana and Leica Bond) and bluing reagent (Ventana only) for 12 minutes. All slides were examined with a Leica DMLB microscope and a 40x ocular lens (field number 25) by at least two hematopathologists. In the BM, quantification of cell types and apoptosis was performed by minimum counts of 10 high-power fields (HPF). BM evaluation was conducted in analogy to morphological assessment of iliac trephine biopsies (Tzankov et al., 2012) . In splenic tissue, cells were counted as percentage of specimen surface.

Immunohistochemical expression was classified by the percentage of stained cells and staining intensity, which we graded as either strong, moderate, weak or absent.

In BM samples, Epstein-Barr encoded ribonucleic acid (EBER RNA), in-situ-hybridization (ISH) was performed using the automated Leica Bond III System in combination with anti-fluorescein antibodies and the BOND Polymer refine detection system, consisting of HRP conjugated antirabbit antibodies. 3,3' DAB was used as chromogen for visualization. Finally, slides were counterstained with hematoxylin.

As control for EBER-ISH results, we performed PCR for determination of viral EBV load.

Deoxyribonucleic acid (DNA) was extracted from biopsy specimens using the Maxwell RSC DNA formalin-fixed paraffin-embedded Kit (Promega). Subsequently, a conserved region of the human Epstein Barr Virus nuclear antigen 1 gene (EBNA1, BKRF1) of EBV was amplified using the ReddyMix PCR Master Mix (Thermo Fisher Scientific), a PCR digoxigenin Labeling Mix (Roche) and a mix of Epstein-Barr 30 and Epstein-Barr 40 primers.

50mg of pulmonary tissue from each COVID-patient was homogenized and RNA was purified subsequently by using the MagNA Pure 96 system and the MagNA Pure 96 DNA and Viral NA Large Volume Kit (Roche) following the manufacturer's instructions. RNA extracts were used for quantitative real-time PCR targeting the SARS-CoV-2 E-gene. Viral RNA was quantified by in vitro RNA transcripts that had been photometrically quantified prior to the study. Total DNA was measured in all extracts using the Qubit dsDNA HS Assay kit (Thermo Fisher Scientific).

Detection of subgenomic RNA (sgRNA) was performed using oligonucleotides targeting the leader transcriptional regulatory sequence and region within the sgRNA coding for the E-gene, as described previously (Wölfel et al., 2020) . Comparisons between dichotomous groups were performed using the Fisher's exact test or the chisquare test. Time from onset to death was analyzed using the Kaplan-Meier method.

We performed autopsy in 11 patients with COVID-19-initiated death and 4 control patients who died from cardiac injuries and were matched for age. Median time from death to autopsy was comparable in both groups (p = 0.6), namely 3 days in COVID-19 patients (IQR 1 -5 days) versus 2 days in the control cohort (IQR 1 -3.5 days). Clinical characteristics and causes of death with COVID-19 are shown in Table 1 .

To characterize the morphology of BM and SPL of COVID-19 patients, we performed histopathologic assessment in comparison to non-COVID-19 controls (Figures 2, 3) . BM from was available from vertebral bodies in all patients. Splenic tissue was obtained from 10 COVID-19 deceased and 3 controls. 73% (n=8) of COVID-19 patients presented with hypercellularity and an increase of immature myelopoiesis with precursors in the BM. Moreover, Megakaryopoiesis was increased in COVID-19 patients with a maximum value of 17 megakaryocytes / HPF as compared to 9 megakaryocytes / HPF in control patients. BM megakaryocytes of COVID-19 patients showed signs of immaturity with cell diameters of < 20 µm and hypolobulated nuclei in 55% (n=6). Peripheral or visceral microthrombi were found in 82% (n=9) of COVID-19 cases but were absent in the control cohort.

CD34 and CD117 positive cells were <5% in the BM of both COVID-19 and control patients.

As compared to the control cohort, 55% (n=6) of COVID-19 patients showed mild fibrosis of the BM medullary space. As a correlate of monocytic activity, variability of monocytic and macrophage cell shapes (round vs. stellar shaped) was observed in 82% (n=9) of COVID-19 patients. However, after EDTA-decalcification macrophage iron load was weak and signs of hemophagocytosis were absent.

In the SPL, we observed a substantial decrease of the white pulp in all COVID-19 deceased but not in the control cohort. CD34+ cells were <5% in all splenic samples. As compared to the BM, we found a moderate intracellular macrophage iron load in 40% (n=4) of COVID-19 SPL which was paired with a thickening of the splenic capsule and the trabecular arterioles and therefore interpreted as a sign of chronic blood retention due to right cardiac insufficiency.

After the basic assessment, we evaluated the lymphatic components of the BM and SPL.

Strikingly, we observed a severe loss of B cells with a subsequent CD20+ B cell depletion in either BM or SPL in 64% of COVID-19 patients (n=7). In the group of patients with B cell loss, CD20+ B cell counts were less or equal to 1% in the BM and 1-5% in the SPL (Figure 3 ). Of these patients, 3 had combined B cell loss in both BM and SPL whereas 2 had either isolated B cell loss in the BM or in the SPL. Moreover, we observed plasma cell depletion in 4 out of 5 patients who had CD20+ B cell loss in the BM. These changes were absent in the control cohort.

Although we did not observe complete CD20+ B cell loss in the remaining 4 COVID-19 decedents, CD20+ B cell counts were still lower than in the control cohort. More precisely, median CD20+ B cell counts were 2% in the BM and 5% in the SPL within the COVID-19 cohort as compared to 7% and 15% in the control cohort ( Figure 2 ). In COVID-19 patients with B cell preservation, the remaining B cells had a tendency towards mixed nodular aggregation (n=4).

Quite contrary to the severe loss of B cells, T cell counts were marginally decreased in the BM of COVID-19 patients (median 10%) as compared to the control cohort (median 12.5%). In the BM, J o u r n a l P r e -p r o o f the maximum T cell/B cell ratio was 10:0 in COVID-19 patients as compared to 3:1 in the control samples. We observed comparable effects of only slight T cell reduction in the SPL ( Figure 2K and Figure 3 ). T cell subpopulations were skewed towards a CD8+ phenotype with CD4/CD8 ratios of in average 1:2 (range 1:1 -1:4) in COVID-19 patients as compared to 1:1 (range 2:1 -1:1) in the BM of the control cohort. Of note, one of the COVID-19 patients had co-infection with HIV and received antiretroviral therapy.

Next, we asked whether severe B cell loss in COVID-19 patients was linked to viral SARS-CoV-2 burden or determined by a specific clinical risk profile. Interestingly, we observed a tendency towards higher SARS-CoV-2 RNA load in pulmonary tissue of patients with complete B cell loss, particularly when the BM was affected. Although median viral copy numbers were approximately equal in both groups (Table 2) , we observed maximum viral copy numbers of nearly 800,000 and 1,150,000/10,000 cells in patients with total B cell loss as compared to 6,500/10,000 cells in patients with B cell preservation.

In order to identify a possible B cell-EBV reactivation during parallel SARS-CoV-2 infection, we performed EBER-ISH in all BM specimens combined with additional PCR clarification. Both techniques revealed an absence of EBV. Clinical characteristics were equally distributed between COVID-19 patients with and without B cell loss (p-values > 0.5 in all pairwise comparisons).

Moreover, intervals from onset of symptoms to death were heterogeneous in both groups ( Table 2) .

Autopsy revealed sepsis due to abscess-forming pneumonia in 27% (n=3) of COVID-19 patients ( Figure 4 ). Of these patients, one belonged to the group harboring B cell loss and two were in the group with B cell preservation. Clinically, these patients were in septic shock prior to death and either swabs or pulmonary lavage showed bacterial superinfection of the underlying COVID-19 J o u r n a l P r e -p r o o f pneumonia with Staphylococcus aureus, Staphylococcus epidermidis or Pseudomonas aeruginosa.

To determine whether sepsis-related immunosuppression had been present prior to death in these three patients, we performed an additional immunological characterization of the BM microenvironment by grading immunohistochemical expression of B-and T-cell markers, HLA-DR, Caspase 3 and PD-L1 in relation to pulmonary SARS-CoV-2 levels and intervals from onset of symptoms to death (Figure 4) . Immunohistochemistry revealed signs of sepsis acquired immunodeficiency in the BM, that were reflected morphologically by an increase of BM cellularity and immature myeloid cell types with multiple myeloid precursors. Furthermore, we observed an increase of T cell apoptosis with more than 200 apoptosis per 10 HPF (characterized by Caspase 3) and an increase of neutrophilic PD-L1 expression in the two patients with fulminant sepsis and early death. These changes were combined with an early loss of B cells and an increase of pulmonary SARS-CoV-2 levels. Furthermore, we observed a continuous decrease in monocytic activation with transition from numerous round shaped CD68-positive monocytes in the BM of those two patients with early death as compared to fewer stellar shaped CD68-positive macrophages in the patient, who died later. The latter was accompanied by a decrease of HLA-DR expression on monocytes, macrophages and dendritic cells, especially in the patient with prolonged sepsis.

This study gives detailed insight into the morphology of bone-marrow and splenic tissue reactions in COVID-19 decedents. To our knowledge, this is the first study examining the specific role of bone marrow B cells in the context of COVID-19-associated lymphocytopenia. Furthermore, we provide information on sepsis-related pathophysiology in patients with COVID-19 pneumonia with pulmonary bacterial co-infection.

Confirmatory to recent COVID-19 autopsy reports, we observed thromboembolic events, bleeding, right cardiac failure and sepsis with abscess-forming pneumonia and consecutive severe pulmonary damage as immediate causes of death (Bryce et al., 2020 , Elezkurtaj et al., 2020 , Lax et al., 2020 , Wichmann et al., 2020 . Median age was 68 years in our cohort and thus comparable to other studies in COVID-19 decedents (Bryce et al., 2020 , Zhou et al., 2020 . Since thromboembolic events, bleeding or sepsis were present in the vast majority (73%) of patients, COVID-19 associated changes in hematopoietic tissue were of particular interest here.

As correlate of hyperinflammation, recent studies have reported excessive macrophage stimulation and signs of consecutive hemophagocytosis in the BM of a subset of COVID-19 patients (Bryce et al., 2020, Merad and Martin, 2020) . Consistent with an acute-phase-reaction, we observed hypercellularity and predominantly immature granulopoiesis with multiple myeloid precursors in the BM, mirrored by a release of immature granulocytes and anemia in the peripheral blood (Figures 1-2) . Furthermore, we found regenerating megakaryopoiesis, that probably resulted from thromboembolic events, which were present in 82% of our cohort and could be explained by hyperinflammation-associated endothelial dysfunction (Bryce et al., 2020 , Varga et al., 2020 . In turn, the latter might have contributed as a mediator for the release of immature granulocytes or myeloid suppressor cells to the periphery via microscopic rupture of the endothelial barrier in the BM (Venet et al., 2020).

Hemophagocytosis was not present in our cohort. Instead, we found signs of incipient sepsis acquired immunodeficiency in the BM of patients with severe bacterial superinfection of COVID-19 pneumonia. This was reflected by an early increase of myeloid PD-L1 expression, lymphocytic apoptosis and macrophage anergy with loss of antigen-presenting capacity (Hotchkiss and Nicholson, 2006 , Huang et al., 2014 , Landelle et al., 2010 . Usually, sepsis acquired immunodeficiency is accompanied by cytokine-related T cell exhaustion, release of myeloid suppressor cells and epigenetically determined monocyte switch to endotoxin tolerance after J o u r n a l P r e -p r o o f bacterial stress (Biswas and Lopez-Collazo, 2009 , Boomer et al., 2011 , Cheng et al., 2016 , Lorente-Sorolla et al., 2019 . Thus, methylation-related predisposition for immune memory adaption may influence the highly variable outcome and affect later immunity in patients with severe bacterial co-infection of COVID-19 pneumonia to a varying extent. However, due to the limited number of cases, these findings need to be interpreted with caution.

Apart from immunodeficiency, severe lymphocytopenia in the peripheral blood has been reported as an adverse risk factor for the clinical outcome of COVID-19 patients (Chen et al., 2020 , Tan et al., 2020 , Terpos et al., Zheng et al., 2020 and there is increasing evidence, that this is caused by a follicular atrophy in lymphoid organs (Bryce et al., 2020 , Buja et al., 2020 , Kaneko et al., 2020 , Lax et al., 2020 . A recent study by Kaneko et al. indicates a crucial impact of TNFα, that leads to an early blockage of B cell lymphoma 6 protein (BCL6)-positive T helper cells with a consecutive loss of BCL6-positive germinal center B cells in early stages of COVID-19 and therefore to a dysregulation of the humoral immune response (Kaneko et al., 2020) . Consistently, we observed severe lymphocytopenia in the peripheral blood, in the SPL and even in the BM in more than half our COVID-19 cohort, which was combined with a release of immature granulocytes, elevated CRP and increased interleukin-6 levels in the peripheral blood (Figure 1 I-L) . This suggested an ongoing acute phase reaction but an inadequate specific immune response in these patients.

Unfortunately, peripheral B/T cell counts were not available in our cohort of COVID-19 decedents. However, in the SPL and in the BM, the severe loss of lymphocytes was predominantly caused by a depletion of B cells rather than by a loss of T-cells (Figures 2 E-F and J-L) . Therefore, our findings strongly emphasize a separate involvement of B cells in the pathogenesis of COVID-19, since viral sepsis usually results in a significant decrease of both CD4+ T cells and CD20+ B cells (Hotchkiss et al., 2001) . In the subgroup of patients with severe B cell loss, pulmonary SARS-CoV-2-levels were exceedingly high, and a distinct clinical risk profile was absent as compared to patients with B cell preservation (Table 2) . Hence, SARS-CoV-2 associated effects were the most J o u r n a l P r e -p r o o f probable link towards the observed B cell loss although the relatively small sample size prevented a detection of statistical significances between the two groups. Furthermore, it should be mentioned that B cell counts in the BM are generally low with median values ranging from 2-5% in the literature (Fauci, 1975) and 7% in our control cohort. Nevertheless, the co-occurrence of both loss of B cells and loss of plasma cells allows for the assumption of an excessive activation of B-cell specific pathways such as the B-cell-transforming-growth-factor-beta-pathway (Chua et al., 2020 , Islam et al., 1991 . The latter seems reasonable, since a recent study by Biasi et al. reports a significant loss of naïve and mature B cells accompanied by an expansion of immunoglobulin M+ plasmablasts in the peripheral blood of patients with COVID-19 pneumonia (De Biasi et al.) .

In analogy to therapy-induced B cell depletion under treatment with Rituximab, systemic immunoglobulin therapy might be helpful in the subset of COVID-19 patients with severe B cell loss.

In conclusion, our findings indicate that infection with SARS-CoV-2 is related to mechanisms of sepsis acquired immunodeficiency as well as B-and plasma cell depletion in hematopoietic tissues.

Since B cells and plasma cells are major key players of acquired immunity, our findings add further explanation to the limited durability of the humoral immune response to SARS-CoV-2 (Kaneko et al., 2020; Long et al., 2020) and thus contribute to the pathophysiological understanding of COVID-19. 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

We gratefully thank Anistan Sebastiampillai, Juliane Plaschke and Franziska Egelhofer for their excellent technical support during the autopsy procedure. Furthermore, we thank Julia Scheider, Sebastian Brünink, and Tobias Bleicker for their help with SARS-CoV-2 RT-PCR testing. 

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Endotoxin tolerance: new mechanisms, molecules and clinical significance

Immunosuppression in Patients Who Die of Sepsis and Multiple Organ Failure

Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response

The Mount Sinai COVID-19 autopsy experience

The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities

Collection and Submission of Postmortem Specimens from Deceased Persons with Known or Suspected COVID-19, Interim Guidance of the Center for Disease Prevention and Control)

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis

COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis

Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID-19 patients with pneumonia

Causes of Death and Comorbidities in Patients with

Human bone marrow lymphocytes. I. Distribution of lymphocyte subpopulations in the bone marrow of normal individuals

Assessment of Deaths From COVID-19 and From Seasonal Influenza

Apoptosis and caspases regulate death and inflammation in sepsis

Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4 T Lymphocytes in Humans

Identification of B7-H1 as a Novel Mediator of the Innate

Immune/Proinflammatory Response as well as a Possible Myeloid Cell Prognostic Biomarker in

TGF-beta 1 induces germ-line transcripts of both IgA subclasses in human B lymphocytes

Estimates of global seasonal influenza-associated respiratory mortality: a modelling study

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19

Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Virological assessment of hospitalized patients with COVID-2019

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Pulmonary SARS-CoV-2 RNA copies, median [IQR] 2. 46